Advanced Proteome Th (APTCF) 0.1232 $APTCF
In an Exclusive Interview the CEO of Advanced Proteome Therapeutics (APC) Discusses the Company's Technology and R&D Strategy
Marketwired - Thu Jan 29, 10:19AM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) announces that APC was profiled in a BioTuesdays.com interview with Leonard Zehr. In the interview, encompassing a wide range of topics, the CEO, Dr. Allen Krantz, discussed the Company's unique approach to developing a potential anti-cancer therapeutic. Dr. Krantz alluded to advantages of the technology, which is designed to combine multiple anti-cancer therapies in a single agent. He pointed out that the agent is not only intended to directly target tumors, but to stimulate the immune system and, in combination with other immunotherapeutic agents, such as the very exciting checkpoint inhibitors, achieve greater overall response rates and durable responses in patients than are currently being observed in the clinic.
APC.VN: 0.185 (+0.015)
Advanced Proteome Therapeutics Engages CRO to Escalate Testing of Promising Cancer Therapy
Marketwired - Wed Nov 12, 12:34PM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has entered into an agreement with one of the world's foremost contract research organizations (CRO). Now, in addition to its in-house programs and academic collaborations, APC will be able to avail itself of the CRO's high quality research models and preclinical and clinical support services to evaluate and accelerate the Company's immuno-oncology program.
APC.VN: 0.185 (+0.015)
APC Announces Positive Results in Combination Cancer Immunotherapy
Marketwire - Thu Sep 11, 8:02AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC) (FRANKFURT: 0E8) is excited to report results from its current round of experiments that not only reinforce previous evidence of the immunotherapeutic properties of APC's protein modification technology, but hold forth the possibility of synergistic effects with other immunotherapies while heralding the entry of a new and potentially powerful approach in the arsenal of anticancer weaponry.
APC.VN: 0.185 (+0.015)
Advanced Proteome Therapeutics Expands Anticancer Studies Base D on Strong Initial Results
Marketwire - Tue Aug 12, 8:28AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company" (TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has expanded and accelerated its anticancer studies to strengthen their commercial prospects because recent positive results with collaborators have demonstrated that modifications of APC's protein delivery system substantially increases antitumor activity and retards tumor growth in animals.
APC.VN: 0.185 (+0.015)
Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST
EDN: 10.76 (+0.32), DL: 18.44 (+0.60), ARAY: 8.00 (+0.24), CTSH: 60.23 (-0.05), APC: 89.44 (+2.13)
Frost & Sullivan: Medical Robots Will Revolutionize Most Surgical Disciplines
M2 - Tue Feb 25, 6:34AM CST
Surgical robots are gaining widespread acceptance across the globe as they enhance the surgeons abilities in terms of surgical imaging, navigation, planning and instrument manipulation. Market participants are conducting extensive research in this field to further strengthen the capabilities of surgeons through advanced imaging techniques, higher degrees of freedom, interactive interfaces, haptics feedback, and teleoperation. Surgical robot manufacturers are also trying to reduce the footprint of existing robotic systems and lessen the invasiveness of surgical procedures by advancing single port, natural orifice, and swarm robotic technologies.
APC.VN: 0.185 (+0.015)
In an Exclusive Interview the CEO of Advanced Proteome Therapeutics (APC) Discusses the Company's Technology and R&D Strategy
Marketwired - Thu Jan 29, 10:19AM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) announces that APC was profiled in a BioTuesdays.com interview with Leonard Zehr. In the interview, encompassing a wide range of topics, the CEO, Dr. Allen Krantz, discussed the Company's unique approach to developing a potential anti-cancer therapeutic. Dr. Krantz alluded to advantages of the technology, which is designed to combine multiple anti-cancer therapies in a single agent. He pointed out that the agent is not only intended to directly target tumors, but to stimulate the immune system and, in combination with other immunotherapeutic agents, such as the very exciting checkpoint inhibitors, achieve greater overall response rates and durable responses in patients than are currently being observed in the clinic. APC.VN: 0.185 (+0.015)
Advanced Proteome Therapeutics Engages CRO to Escalate Testing of Promising Cancer Therapy
Marketwired - Wed Nov 12, 12:34PM CST
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has entered into an agreement with one of the world's foremost contract research organizations (CRO). Now, in addition to its in-house programs and academic collaborations, APC will be able to avail itself of the CRO's high quality research models and preclinical and clinical support services to evaluate and accelerate the Company's immuno-oncology program. APC.VN: 0.185 (+0.015)
APC Announces Positive Results in Combination Cancer Immunotherapy
Marketwire - Thu Sep 11, 8:02AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC) (FRANKFURT: 0E8) is excited to report results from its current round of experiments that not only reinforce previous evidence of the immunotherapeutic properties of APC's protein modification technology, but hold forth the possibility of synergistic effects with other immunotherapies while heralding the entry of a new and potentially powerful approach in the arsenal of anticancer weaponry. APC.VN: 0.185 (+0.015)
Advanced Proteome Therapeutics Expands Anticancer Studies Base D on Strong Initial Results
Marketwire - Tue Aug 12, 8:28AM CDT
Advanced Proteome Therapeutics Corporation ("APC" or the "Company"
(TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to announce that it has expanded and accelerated its anticancer studies to strengthen their commercial prospects because recent positive results with collaborators have demonstrated that modifications of APC's protein delivery system substantially increases antitumor activity and retards tumor growth in animals. APC.VN: 0.185 (+0.015)
Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST
EDN: 10.76 (+0.32), DL: 18.44 (+0.60), ARAY: 8.00 (+0.24), CTSH: 60.23 (-0.05), APC: 89.44 (+2.13)
Frost & Sullivan: Medical Robots Will Revolutionize Most Surgical Disciplines
M2 - Tue Feb 25, 6:34AM CST
Surgical robots are gaining widespread acceptance across the globe as they enhance the surgeons abilities in terms of surgical imaging, navigation, planning and instrument manipulation. Market participants are conducting extensive research in this field to further strengthen the capabilities of surgeons through advanced imaging techniques, higher degrees of freedom, interactive interfaces, haptics feedback, and teleoperation. Surgical robot manufacturers are also trying to reduce the footprint of existing robotic systems and lessen the invasiveness of surgical procedures by advancing single port, natural orifice, and swarm robotic technologies.
APC.VN: 0.185 (+0.015)
